Michael Schwarz

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Collaborators (10)

Teresa Binter

Medical University of Vienna

AUSTRIA

View details

Georg Semmler

Medical University of Vienna

AUSTRIA

View details

Minneke J. Coenraad

NETHERLANDS

View details

Lukas Hartl

Medical University of Vienna

AUSTRIA

View details

Lorenz Balcar

Medical University of Vienna

AUSTRIA

View details

Albert Stättermayer

Medical University of Vienna

AUSTRIA

View details

Michael Trauner

Professor of Medicine and Chair of Gastroenterology and Hepatology

Medical University of Vienna

AUSTRIA

View details

Jeremy V Camp

Medical University of Vienna

AUSTRIA

View details

Benedikt Simbrunner

Medical University of Vienna

AUSTRIA

View details

Thomas Reiberger

Medical University of Vienna

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Schwarz

Research Interests

Explore related searches

Contact this professor

Articles (28)

Diagnostic and Clinical Implications of High Spleen-To-Liver Stiffness Ratio in MASH-A Prospective, Comparative Study.

Chronic hepatitis E in a patient after chimeric antigen receptor‐T‐cell treatment for diffuse large B‐cell lymphoma and rapid progression towards decompensated liver cirrhosis

Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis

The Vasopressin Biomarker Copeptin is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades

Intrauterine blood transfusion causes dose- and time-dependent signal alterations in the liver and the spleen on fetal magnetic resonance imaging

Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure

Letter: Insulin‐Like Growth Factor‐1 in Cirrhosis Is Linked to Hepatic Dysfunction and Fibrogenesis and Predicts Liver‐Related MortAlity—Authors' Reply

Insulin-like growth factor-1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver-related mortality

Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality

High histamine levels are associated with acute‐on‐chronic liver failure and liver‐related death in patients with advanced chronic liver disease

Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta

Diagnostic and prognostic performance of the LiverRisk score in tertiary care☆

Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.

The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity—A prospective biopsy‐controlled study

Statins, metformin, and RAS inhibitors did not reduce variceal bleeding risk and mortality in a large, real-life cohort of patients with cirrhosis

Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality

An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression

Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers

Diffuse idiopathic skeletal hyperostosis as a cause for dysphagia in a patient with ankylosing spondylitis

Endoscopic band ligation is safe despite low platelet count and high INR

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis

HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease

Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients

Collaborators (10)

Teresa Binter

Georg Semmler

Minneke J. Coenraad

Lukas Hartl

Lorenz Balcar

Albert Stättermayer

Michael Trauner

Jeremy V Camp

Benedikt Simbrunner

Thomas Reiberger

Make your next move.